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The principle investigator has made substantial progress in executing the statement of work outlined in the proposal. In addition he has fulfilled the requirements mandated by his training program to date. First, the PI obtained the human C5 cDNA and substituted a PSA substrate sequence in place of the wild type activation sequence. Modifications were implemented based on results from homology modeling. Next, PSA mediated cleavage was confirmed by mass spectrometry. Recombinant production of the confirmed PSA cleavable C5 mutant was scaled up by an adenovirus for in vitro assays. Purification of the recombinant protein is ongoing. Finally, the PI has begun working on a similar project that uses a different strategy to target prostate cancer cells in an androgen and growth-independent manner.
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Introduction:
The principle investigator (PI) has made substantial progress in fulfilling the goals outlined in the statement of work. Several major unforeseen challenges have been surmounted. The PI has completed his thesis proposal and formed a five-member thesis committee that has since met twice. The PI assisted his mentor in the application for additional funding. Finally, the PI has begun working on a similar project that uses a different strategy to target prostate cancer cells in an androgen and growth-independent manner.
Body:
Specific Aim 1 -Obtain human C5 cDNA and substitute a PSA substrate sequence in place of the wild type activation sequence; amend a purification tag to the terminus of C5 to aid in its purification.
[Completed]
The C5 cDNA was mutated via site-directed mutagenesis to include a PSA recognition sequence in place of the wild type activation sequence. The resulting construct was named PAC-1. PAC-1 was transfected into COS-7 cells and the supernatant containing the recombinant protein was collected. Because of the chance the purification tag could alter the conformation and thus hinder the PSA mediated cleavage, we decided to add the tag on after cleavage was observed (in Specific Aim 2). The recombinant protein collected above was characterized for PSA mediated cleavage by western blot analysis. Briefly, purified human PSA (Calbiochem) was incubated at 10µg/mL in the conditioned media containing the recombinant protein. The protein solution was then analyzed for cleavage by western blot using a C5 antibody (Santa Cruz Biotechnology). Cleavage would be verified by a shift in molecular weight. Unfortunately, no shift was observed.
Following the guide of Ogata and Low[1], we made a series of mutants (Figure 1) incorporating more of the semenogelin II sequence, the known physiological substrate for PSA. In all, six more mutants were generated. Meanwhile, the mutants were examined in silico for subtle structural changes which may render them PSA sensitive. Briefly, homology modeling was performed using the SWISS-MODEL [2] homology modeling server via the automated mode using the published crystal structure of C5 as a template (PDB 3CU7) [3] . The homology models suggested adding six more residues of semenogelin II to the left of the PSA recognition sequence and seven more residues of semenogelin II to the right would result in a α-helix containing the "HSSKLQ" PSA substrate sequence being exposed to the solvent (Figure 2 ). This mutant was named PAC-2. A plasmid containing PAC-2 was transfected into COS-7 and HEK293T cells and conditioned media containing the recombinant protein was collected. For unknown reasons expression levels of PAC-2 were substantially lower in both cell lines. The recombinant PAC-2 was analyzed for PSA mediated cleavage by western blot as described above. Unfortunately, no shift was observed, although signal was weak and irreproducible because of low protein levels. We suspected some cleavage might actually be occurring, but at subprime levels. This combined with the small amount of PAC-2 protein made analysis by western blot problematic.
As a more sensitive way to probe for PSA mediated PAC-2 cleavage, we analyzed PSA treated conditioned media by MALDI-TOF mass spectroscopy. In this experiment, wild type C5 was completely resistant to cleavage by PSA and no release of 11 kDa fragment was observed (Figure 3) . In contrast, incubation of the PAC5-2 protein resulted in production of an ~11kDa fragment corresponding to the modified N-terminal portion of the PAC5-2 protein. Based on the MALDI results, high resolution LTQ nanoHPLC/Orbitrap mass spectroscopic analysis was performed to obtain high resolution mass. Sequencing of this mass fragment using the Sequest sequencing algorithm confirmed the correct sequence corresponding to the 80 amino acid Nterminal C5 cleavage product 
